First Patient Dosed in Phase II Renal Cancer Theranostics Study
MELBOURNE, Australia and INDIANAPOLIS, May 5, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in the 'STARLITE 2' Phase II study of the Company's investigational renal cancer therapy, TLX250 (177 Lu-DOTA-girentu...
Telix Further Strengthens European Distribution Network for Illuccix
MELBOURNE, Australia and LIÈGE, Belgium, April 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces agreements with Sociedade Avanço, Unipessoal, LDA (Avanço) and THP Medical Products Vertriebs GmbH (THP) for the distribution of Telix's prostate ca...
First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent
Physicians in Indiana, New York City, and Washington are among the first to administer Illuccix® – demonstrating coast-to-coast availability of this new imaging agent Typically diagnosed in men over 50, prostate cancer is the second leading cause of cancer death in American men, after lung cance...
ProstACT Update: TARGET Study Ethics Approval
MELBOURNE, Australia, April 12, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its ProstACT TARGET Phase II clinical trial of the Company's prostate cancer antibody therapy candidate TLX591 (177Lu-DOTA-rosopatamab), in patients experiencing a fir...
Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab
MELBOURNE, Australia and INDIANAPOLIS, April 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, "Telix", the "Company") today announces that it has entered into a licence agreement with Eli Lilly and Company ("Lilly") under which Telix is granted exclusive worldwide rights to devel...
PSMA-PET Imaging to be Funded through Medicare in Australia from July 2022
MELBOURNE, Australia, April 6, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) welcomes the listing of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) (PSMA-PET) imaging for patients with prostate cancer on the Medicare Benefits Sche...
Telix, GMS and Monash Awarded $23M Federal Government Funding as part of $71M Australian Precision Medicine Enterprise (APME) Project
MELBOURNE, Australia, April 4, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it is part of a $71.2 million Australian Precision Medicine Enterprise (APME) Project, which has been awarded$23 million in Federal Government grant funding under t...
Commercial Launch: Illuccix® Now Available to Order in the United States
MELBOURNE, Australia and INDIANAPOLIS, April 4, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga 68 gozetotide), also known as68Ga-PSMA-11 injection, is now commercially...
Change of Composition of the Telix Board of Directors
* Non-Executive Director Oliver Buck to retire at the Annual General Meeting * Tiffany Olson, experienced U.S.-based pharma executive appointed as independent Non-Executive Director MELBOURNE, Australia and INDIANAPOLIS, March 31, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, T...
New Video Series "PSMA PET/CT TODAY" Discusses the Future of Prostate Cancer Care with Leading Experts
MELBOURNE, Australia and INDIANAPOLIS, March 29, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the launch of PSMA PET/CT[1] Today, a five-part video series, featuring leading theranostics experts, on the role of advanced diagnostic imaging in pr...
Telix Granted FDA Orphan Drug Designation for Bone Marrow Conditioning Treatment
MELBOURNE, Australia and INDIANAPOLIS, March 29, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for TLX66 (90Y-besilesomab), for conditioning trea...
Telix and Xiel Sign U.K. and Ireland Distribution Agreement for Illuccix®
MELBOURNE, Australia and LIÈGE, Belgium, March 29, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed an exclusive agreement with Xiel Limited (Xiel) for the distribution of Telix's prostate cancer investigational imaging product, Illuc...
Telix Advances Development of Glioblastoma Therapy Program
MELBOURNE, Australia, March 23, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces it has made significant progress in advancing the Company's glioblastoma multiforme (GBM) therapy candidate TLX101 into the next stage of clinical development. TLX101 (4-L-...
